Marker Gene Technologies sells itself. The company offers drug researchers a variety of marker genes for monitoring gene expression, intracellular targeting, and other purposes. The company's marker genes are used in research for agricultural biotechnology, cell culturing, and bacteriology. Additional products include reagents, enzyme substrates and kits, and other molecular biology products. Marker Gene Technologies also maintains four fully equipped laboratories from which it provides contract research services for biotechnology and pharmaceutical clients. The firm markets its products through a number of distributors in the US and abroad, in Europe, Asia, and the Middle East.

Nile Therapeutics, Inc. company was founded in 2005 and is based in San Mateo, California. Nile Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics for the treatment of cardiovascular disease and other areas of unmet medical needs. The company focuses on developing its lead compound, CD-NP, a novel rationally designed chimeric peptide in clinical studies for the treatment of heart failure. CD-NP was designed to reduce symptoms of dyspnea in heart failure patients through both a reduction in intracardiac pressure and an improvement in renal function. Nile is also developing CU-NP, a novel, rationally designed natriuretic peptide.

The Westaim Corporation was founded in 1996. The Westaim Corporation, a holding company, develops, manufactures and commercializes medical products that fight infection and inflammation. Nucryst Pharmaceuticals Corp. Nucryst develops, manufactures and commercializes innovative medical products that fight infection and inflammation. Wound Care Products: Acticoat Burn Dressings and Acticoat 7 Dressings, targeting the burn and chronic wound markets, were developed and sold by Nucryst. Nucryst's license to Smith & Nephew grants Smith & Nephew the exclusive worldwide right to market, distribute and sell Acticoat products using Nucryst's SILCRYST coatings for use on non-minor dermal wounds or burns in humans, including improvements to those products, and any new products developed with Smith & Nephew using Nucryst's SILCRYST coatings or powders in the Field. There are six product families with SILCRYST coatings manufactured by Nucryst for Smith & Nephew at its Fort Saskatchewan plant: Acticoat Burn, Acticoat 7, Acticoat Absorbent, Acticoat Moisture Control, Acticoat Site, and Acticoat Post-Op. In 2008, Nucryst announced that Health Canada granted marketing approval for a new SILCRYST product, Acticoat Flex Barrier Dressing. Agreements with Smith & Nephew: In 2007, Nucryst signed amended agreements with Smith & Nephew for the manufacture and sale of Acticoat products.

Medifacts was founded in 1985 as Core Laboratory Services and has facilities in the US, Germany, and China. Medifacts International, Inc. company specializes in cardiovascular safety data management services, including ECG (electrocardiogram) and ambulatory blood pressure monitoring services, for clients conducting pharmaceutical, biotech, and medical device development trials. It also provides data collection, consulting, training, and telemedicine services. The company has sold its Clinical Research Services division, which offered broader data management services for clinical trials.

Diversa Limited company has developed biosensor technology, drawing on work from the fields of biotechnology, nanotechnology, and electronics. Its primary technology is the Ion Channel Switch, a biosensing device. The Ion Channel Switch, or ICS, technology was developed using a membrane that acts as a switch, triggering an electrical current in the presence of particular molecules. Diversa plans to use the technology in point-of-care diagnostic products. The ICS was developed from research done by the Australian Membrane and Biotechnology Research Institute (AMBRI), the University of Sydney, and others.

Aldagen's work stems from the need for tissue repair. The biopharmaceutical company develops cell regeneration therapies using adult stem cells. It uses a proprietary technology that isolates an enzyme known as aldehyde dehydrogenase, or ALDH, which it believes can target a number of diseases. Aldagen hopes its products will be used to treat hereditary metabolic diseases in children, leukemia, and cardiovascular diseases; all its drugs are in the development stage. The company does its own manufacturing and plans to do its own marketing. Venture capital firm Intersouth Partners holds about 42% of Aldagen, which filed an IPO in late 2009. The company is led by CEO W. Thomas Amick.

Icagen, Inc. company was founded in 1992 and is based in Durham, North Carolina. Icagen, Inc. (Icagen) is a biopharmaceutical company focused on the discovery, development and commercialization of orally-administered small molecule drugs that modulate ion channel targets. The Company’s programs include ICA-105665 for epilepsy and neuropathic pain, for which the Company is conducting a Phase I multiple ascending dose study in healthy volunteers and epilepsy patients and Senicapoc, previously referred to as ICA-17043, for asthma, for which the Company is conducting two Phase II proof-of-concept clinical trials.

Astellas Pharma US, Inc. company's primary products include organ transplant immunosuppressant Prograf, overactive bladder treatment VESIcare, and vascular dilator Andenoscan. It is focusing its efforts on the following therapeutic areas: cardiology, dermatology, immunology, infectious diseases, and urology. The company's other products include antifungals Mycamine and AmBisome, enlarged prostate treatment Flomax, and dermatological product Protopic. Astellas Pharma US is a subsidiary of Astellas Pharma, which was formed in 2005 with the merger of Japan-based pharmaceutical companies Yamanouchi and Fujisawa.

Samaritan Pharmaceuticals, Inc. was founded in 1994 and is based in Las Vegas, Nevada. Samaritan Pharmaceuticals, Inc. (Samaritan) is an entrepreneurial biopharmaceutical company, focused on commercializing therapeutic products to relieve the suffering of patients with Alzheimer's disease, cancer, cardiovascular disease, human immunodeficiency virus (HIV), and Hepatitis C. Samaritan also focuses on commercializing its acquired marketing and sales rights to sell marketed revenue-generating products, in Greece, and/or various Eastern European countries. The Company has partnered its oral entry inhibitor HIV drug SP-01A, a drug that has demonstrated efficacy, in Phase II clinical trials, with Pharmaplaz, Ireland to advance to Phase III clinical trials. In addition, it focuses on commercializing three market drug candidates with late-stage preclinical development programs.

Gemini Pharmaceuticals' private label products are formulated to be as effective as their name-brand twins. The company makes prescription and OTC pharmaceuticals and nutritional supplements, including acetaminophen, vitamin B-12, and herbal enhancers. Its pharmaceutical offerings include cough and cold medications, pain relievers, and sleeping aids. Its supplement product line starts with such basics as vitamins and minerals, and then includes what it calls "specialty products" such as energy boosters and weight loss supplements. Gemini Pharmaceuticals also makes pet care supplements such as joint support and allergy relief and prescription prenatal vitamins and other custom formulations.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.